Feprazone Prevents Free Fatty Acid (FFA)-Induced Endothelial Inflammation by Mitigating the Activation of the TLR4/MyD88/NF-κB Pathway

Increased levels of free fatty acid (FFA)-induced endothelial dysfunction play an important role in the initiation and development of atherosclerosis. Feprazone is a nonsteroidal anti-inflammatory compound. However, the beneficial effects of feprazone on FFA-induced endothelial dysfunction have not been reported before. In the current study, we found that treatment with feprazone ameliorated FFA-induced cell death of human aortic endothelial cells (HAECs) by restoring cell viability and reducing the release of lactate dehydrogenase (LDH). Importantly, we found that treatment with feprazone ameliorated FFA-induced oxidative stress by reducing the production of mitochondrial reactive oxygen species (ROS). In addition, feprazone prevented FFA-induced expression and secretion of proinflammatory cytokines and chemokines, such as chemokine ligand 5 (CCL5), interleukin-6 (IL-6), and interleukin-8 (IL-8). We also found that feprazone decreased the expression of matrix metalloproteinase-2 (MMP-2) and matrix metalloproteinase-9 (MMP-9). Interestingly, we found that feprazone reduced the expression of cell adhesion molecules, such as vascular cell adhesion molecule-1 (VCAM-1) and intercellular cell adhesion molecule-1 (ICAM-1). Our results also demonstrate that feprazone prevented FFA-induced activation of the toll-like receptor 4 (TLR4)/myeloid differentiation factor 88 (MyD88)/nuclear factor kappa-B (NF-κB) signaling pathway. These findings suggest that feprazone might serve as a potential agent for the treatment of atherosclerosis by improving the endothelial function.

[1]  Wenliang Chen,et al.  Upregulation of CFTR Protects against Palmitate-Induced Endothelial Dysfunction by Enhancing Autophagic Flux , 2020, Oxidative medicine and cellular longevity.

[2]  C. Ginies,et al.  n-6 Polyunsaturated fatty acid oxidation increase oxidative stress, endothelial dysfunction and atherosclerosis in ApoE mice fed with chronic Western diet. Prevention strategy by apple polyphenols , 2020 .

[3]  S. Brar,et al.  Non-steroidal anti-inflammatory drugs in the environment: Where were we and how far we have come? , 2020, Environmental pollution.

[4]  K. Rahimi,et al.  Global and regional prevalence, burden, and risk factors for carotid atherosclerosis: a systematic review, meta-analysis, and modelling study. , 2020, The Lancet. Global health.

[5]  Bo Hu,et al.  Infection and atherosclerosis: TLR-dependent pathways , 2020, Cellular and Molecular Life Sciences.

[6]  E. Bonifazi.  Paracetamol-induced fixed erythema. , 2019 .

[7]  X. Liang,et al.  Neutrophil extracellular traps induced by IL-8 aggravate atherosclerosis via activation NF-κB signaling in macrophages , 2019, Cell cycle.

[8]  Chandragouda R. Patil,et al.  Animal Models of Inflammation for Screening of Anti-inflammatory Drugs: Implications for the Discovery and Development of Phytopharmaceuticals , 2019, International journal of molecular sciences.

[9]  E. Wiemer,et al.  Major vault protein suppresses obesity and atherosclerosis through inhibiting IKK–NF-κB signaling mediated inflammation , 2019, Nature Communications.

[10]  K. Ley,et al.  Immunity and Inflammation in Atherosclerosis , 2019, Circulation research.

[11]  Dan Liu,et al.  Carotid thickness and atherosclerotic plaque stability, serum inflammation, serum MMP-2 and MMP-9 were associated with acute cerebral infarction , 2018, Experimental and therapeutic medicine.

[12]  C. Morillas,et al.  Obesity impairs leukocyte‐endothelium cell interactions and oxidative stress in humans , 2018, European journal of clinical investigation.

[13]  M. Hirata,et al.  Relationship between circulating VCAM-1, ICAM-1, E-selectin and MMP9 and the extent of coronary lesions , 2018, Clinics.

[14]  E. Miller,et al.  Selective inhibition of endothelial NF-κB signaling attenuates chronic intermittent hypoxia-induced atherosclerosis in mice. , 2018, Atherosclerosis.

[15]  Jason L Johnson,et al.  Metalloproteinases in atherosclerosis , 2017, European journal of pharmacology.

[16]  K. Stamatelopoulos,et al.  Platelet-derived chemokines in inflammation and atherosclerosis. , 2017, Cytokine.

[17]  Bing Pan,et al.  AG1296 enhances plaque stability via inhibiting inflammatory responses and decreasing MMP-2 and MMP-9 expression in ApoE-/- mice. , 2017, Biochemical and biophysical research communications.

[18]  Arijit Ghosh,et al.  Role of free fatty acids in endothelial dysfunction , 2017, Journal of Biomedical Science.

[19]  A. Reiss,et al.  Interleukin-6 in atherosclerosis: atherogenic or atheroprotective? , 2017 .

[20]  P. Sudhakaran,et al.  Quercetin attenuates atherosclerotic inflammation and adhesion molecule expression by modulating TLR-NF-κB signaling pathway. , 2016, Cellular immunology.

[21]  K. Peter,et al.  Atherosclerotic Plaque Rupture: Identifying the Straw That Breaks the Camel's Back. , 2016, Arteriosclerosis, thrombosis, and vascular biology.

[22]  R. Toche.  Synthesis of Nitriles – Synthesis of 4-Cyano Pyrazole, 5-Aminopyrazole Derivatives and the Deamination of 5-Aminopyrazole Derivatives , 2016 .

[23]  W. Frishman,et al.  Inflammation and Atherosclerosis: A Review of the Role of Interleukin-6 in the Development of Atherosclerosis and the Potential for Targeted Drug Therapy , 2014, Cardiology in review.

[24]  K. Umezawa,et al.  Enhanced NF-κB Activity Impairs Vascular Function Through PARP-1–, SP-1–, and COX-2–Dependent Mechanisms in Type 2 Diabetes , 2013, Diabetes.

[25]  M. Hashizume,et al.  Atherogenic effects of TNF-α and IL-6 via up-regulation of scavenger receptors. , 2012, Cytokine.

[26]  D. Spandidos,et al.  Interleukin 8 and cardiovascular disease. , 2009, Cardiovascular research.

[27]  Jae-Jin Lee,et al.  Resveratrol inhibits foam cell formation via NADPH oxidase 1-mediated reactive oxygen species and monocyte chemotactic protein-1 , 2009, Experimental & Molecular Medicine.

[28]  Chun-Yin Huang,et al.  CCL5 increases lung cancer migration via PI3K, Akt and NF-kappaB pathways. , 2009, Biochemical pharmacology.

[29]  G. Kollias,et al.  Endothelial cell-specific NF-kappaB inhibition protects mice from atherosclerosis. , 2008, Cell metabolism.

[30]  L. Laury-Kleintop,et al.  The select cyclooxygenase-2 inhibitor celecoxib reduced the extent of atherosclerosis in apo E-/- mice. , 2008, The Journal of surgical research.

[31]  J. Egido,et al.  Overexpression of COX-2, Prostaglandin E synthase-1 and prostaglandin E receptors in blood mononuclear cells and plaque of patients with carotid atherosclerosis: regulation by nuclear factor-kappaB. , 2006, Atherosclerosis.

[32]  F. Cipollone,et al.  COX-2 and Atherosclerosis , 2006, Journal of cardiovascular pharmacology.

[33]  J. Morrow,et al.  Cyclooxygenase-2 promotes early atherosclerotic lesion formation in ApoE-deficient and C57BL/6 mice. , 2005, Journal of molecular and cellular cardiology.

[34]  J. Keaney,et al.  AMPK inhibits fatty acid-induced increases in NF-kappaB transactivation in cultured human umbilical vein endothelial cells. , 2004, Biochemical and biophysical research communications.

[35]  R. Muraro,et al.  Blockade of the Angiotensin II Type 1 Receptor Stabilizes Atherosclerotic Plaques in Humans by Inhibiting Prostaglandin E2–Dependent Matrix Metalloproteinase Activity , 2004, Circulation.

[36]  I. Alexa,et al.  [Oxidative stress in atherosclerosis]. , 2003, Revista medico-chirurgicala a Societatii de Medici si Naturalisti din Iasi.

[37]  H. Qi.  EFFECTS OF FEPRAZONE ON CYCLOOXYGENASE IN VITRO , 2000 .

[38]  P. Libby,et al.  Augmented expression of cyclooxygenase-2 in human atherosclerotic lesions. , 1999, The American journal of pathology.

[39]  D. Parke,et al.  The micro gas-liquid chromatographic analysis of 4-(3',3'-dimethylallyl)-1,2-diphenylpyrazolidine-3,5-dione (feprazone) in human biosamples. , 1988, Journal of pharmaceutical and biomedical analysis.